Shire bags rights to bi-specific antibody for haemophilia
Shire has snapped up exclusive worldwide rights from Novimmune for an innovative, bispecific antibody currently in preclinical development for the treatment of patients with haemophilia A and haemophilia A with inhibitors.
Read More
